Dissociation of secretory responses to low-calcium and beta-adrenergic stimulation in primary hyperparathyroidism. 1987

N Kane-Johnson, and L Strasik, and E S Orwoll

We have used a parathyroid cell perifusion system to evaluate the secretory responses to low-calcium and beta-adrenergic stimuli in series of 13 adenomatous human parathyroid tissues. In cells from all chief cell adenomas PTH secretion could be influenced by changes in extracellular calcium concentrations (either an increase in response to lower calcium concentrations or a decrease following an increase in calcium levels). However, there was marked heterogeneity in the PTH secretory response to adrenergic stimulation. In most instances, adenomatous parathyroid tissue also responded quickly and vigorously to beta-adrenergic agents (mean increase in secretion 322% +/- 52 (SEM) over baseline), although five of the 13 tissues clearly showed no PTH secretory response. Furthermore, there was a dissociation between the responses to adrenergic and low-calcium stimulation in that the presence or magnitude of the response to one type of stimulus could not be used to predict the nature of the response to the other. Studies of cells from an oxyphil adenoma revealed a very vigorous response to adrenergic stimulation (1,400% over baseline), but no response to changes in extracellular calcium concentrations. These results indicate that human parathyroid tissue is capable of a marked secretory response to adrenergic stimulation. The dissociation between secretory responses to low-calcium conditions and adrenergic agents suggests that the mechanisms of secretion by low-calcium and adrenergic stimuli in adenomatous human parathyroid tissue are to some degree independent. Furthermore, aberrancies in the neoplastic parathyroid process apparently may affect either of these two secretory mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D010280 Parathyroid Glands Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body. Gland, Parathyroid,Glands, Parathyroid,Parathyroid Gland
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010282 Parathyroid Neoplasms Tumors or cancer of the PARATHYROID GLANDS. Cancer of Parathyroid,Parathyroid Cancer,Cancer of the Parathyroid,Neoplasms, Parathyroid,Parathyroid Adenoma,Parathyroid Carcinoma,Adenoma, Parathyroid,Adenomas, Parathyroid,Cancer, Parathyroid,Cancers, Parathyroid,Carcinoma, Parathyroid,Carcinomas, Parathyroid,Neoplasm, Parathyroid,Parathyroid Adenomas,Parathyroid Cancers,Parathyroid Carcinomas,Parathyroid Neoplasm
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D004837 Epinephrine The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic

Related Publications

N Kane-Johnson, and L Strasik, and E S Orwoll
February 1975, Postgraduate medical journal,
N Kane-Johnson, and L Strasik, and E S Orwoll
August 1965, The American journal of physiology,
N Kane-Johnson, and L Strasik, and E S Orwoll
November 1985, Endocrinology,
N Kane-Johnson, and L Strasik, and E S Orwoll
December 1980, Biological psychiatry,
N Kane-Johnson, and L Strasik, and E S Orwoll
March 1996, American journal of respiratory and critical care medicine,
N Kane-Johnson, and L Strasik, and E S Orwoll
November 1985, Kokyu to junkan. Respiration & circulation,
N Kane-Johnson, and L Strasik, and E S Orwoll
January 2000, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!